PharVision Advisers’s Pentair PNR Stock Holding History

PharVision Advisers’s Portfolio PNR Stock Details PNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,663	Closed	-$268K	–	466
2024 Q4	$268K	Buy	+2,663	New	+$273K	0.23%	191

Other funds holding PNR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's PNR Position: Q1 2025 in Review

PharVision Advisers sold out of Pentair (PNR) in Q1 2025, closing a stake of 2,663 shares — an estimated $268K sold.

PharVision Advisers first reported a position in PNR in Q4 2024 and held it in 1 quarter. The position peaked at $268K in Q4 2024. 725 funds tracked by Wall St. Rank hold PNR as of Q1 2025.

PharVision Advisers reported no remaining Pentair position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 2,663 Pentair shares in Q1 2025, an estimated $268K.
PharVision Advisers first reported a position in Pentair in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Pentair position peaked at $268K in Q4 2024.
725 funds tracked by Wall St. Rank held Pentair as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.